|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases显示文摘Inflammatory bowel diseases (IBDs) such as Crohn's disease are highly debilitating. There are inconsistencies in response to and side effects in the current conventional medications, failures in adequate drug delivery, and the lack of therapeutics to offer complete remission in the presently available treatments of IBD. This suggests the need to explore beyond the horizons of conventional approaches in IBD therapeutics. This review examines the arena of the evolving IBD nanomedicine, studied so far in animal and in vitro models, before comprehensive clinical testing in humans. The investigations carried out so far in IBD models have provided substantial evidence of the nanotherapeutic approach as having the potential to overcome some of the current drawbacks to conventional IBD therapy. We analyze the pros and cons of nanotechnology in IBD therapies studied in different models, aimed at different targets and mechanisms of IBD pathogenesis, in an attempt to predict its possible impact in humans. | Madharasi VA Pichai Lynnette R Ferguson | 2012 | World Journal of Gastroenterology2012，18，23： | 19 |
| 2 | Regulation of Seed Vigor by Manipulation of Raffinose Family Oligosaccharides in Maize and Arabidopsis thaliana显示文摘棉白糖家庭 oligosaccharides (RFO ) 在许多植物种类在成熟干燥期间在种子积累。然而, RFO 是否在建立种子活力有一个角色,仍然保持不清楚。GALACTINOL SYNTHASE (GOLS ) ,棉白糖 SYNTHASE (RS ) ,和 STACHYOSE SYNTHASE (圣) 是为 RFO 负责的酶 ? 在植物的生合成。有趣地,仅仅棉白糖在玉米种子被检测,并且唯一的玉米 RS 基因(ZmRS ) 被识别。在这研究,我们发现二独立 mutator (亩) 打断了 zmrs 线,不包含棉白糖但是 hyperaccumulating galactinol, ? 显著地减少了种子活力,与空 segregant 控制相比。不同于玉米, Arabidopsis thaliana 种子包含几 RFO (棉白糖, stachyose,和 verbascose ) 。A 的操作。thaliana RFO ? 由 overexpressing ZmGOLS2, ZmRS,或 AtSTS 的内容表明了那 co-overexpression ZmGOLS2 和 ZmRS,或 ZmGOLS2 的 overexpression 独自一个,显著地增加了 RFO 的全部的内容并且提高了 Arabidopsis 种子活力。令人惊讶地,当 ZmRS 的 overexpression 增加了种子棉白糖内容时,它的 overexpression 戏剧性地减少了种子活力并且减少了 galactinol, stachyose,和 verbascose 的种子数量。相反, atrs5 异种种子类似于关于种子活力和 RFO 内容的野类型的那些,除了 stachyose 它在 atrs5 种子积累了。全部的 RFO, RFO/sucrose 比率,然而并非绝对单个 RFO ? 数量,断然与 A 相关。thaliana 种子活力, stachyose 和 verbascose 多于棉白糖作出贡献到。一起拿,这些结果提供新卓见进种子活力的规章的机制并且在 monocot 和 dicot 在 modulating 种子活力为 RFO 揭示不同要求。 | Tao Li Yumin Zhang Dong Wang Ying Liu Lynnette M.A. Dirk Jack Goodman A. Bruce Downie Jianmin Wang Guoying Wang Tianyong Zhao | 2017 | Molecular Plant2017，10，12： | 13 |
| 3 | Why interleukin-10 supplementation does not work in Crohn's disease patients显示文摘Inflammatory bowel diseases (IBD) such as Crohn's disease (CD) or ulcerative colitis are chronic intestina disorders, which are on the increase in 'Westernised' countries. IBD can be caused by both genetic and environmental factors. Interleukin-10 (IL-10) is an immunoregulatory cytokine that has been identified as being involved in several diseases including IBD. Studies have shown that polymorphisms in the promoter region reduce serum levels of IL-10 and this reduction has been associated with some forms of IBD. Mouse models have shown promising results with IL-10 supplementation, as such IL-10 supplementation has been touted as being a possible alternative treatment for CD in humans. Clinical trials have shown that recombinant human IL-10 is safe and well tolerated up to a dose o 8 μg/kg. However, to date, the results of the clinica trials have been disappointing. Although CD activity was reduced as measured by the CD activity index IL-10 supplementation did not result in significantly reduced remission rates or clinical improvements when compared to placebo. This review discusses why IL-10supplementation is not effective in CD patients currently and what can be addressed to potentially make IL-10 supplementation a more viable treatment option in the future. Based on the current research we conclude that IL-10 supplementation is not a one size fits all treatment and if the correct population of patients is chosen then IL-10 supplementation could be of benefit. | Gareth J Marlow Dominique van Gent Lynnette R Ferguson | 2013 | World Journal of Gastroenterology2013，19，25： | 9 |
| 4 | Single nucleotide polymorphism in the tumor necrosis factor-alpha gene affects inflammatory bowel diseases risk显示文摘AIM: To investigate the role that single nucleotide polymorphisms (SNPs) in the promoter of the tumour necrosis factor-alpha (TNF-α) gene play in the risk of inflammatory bowel diseases (IBDs) in a New Zealand population, in the context of international studies. METHODS: DNA samples from 388 patients with Crohn's disease (CD), 405 ulcerative colitis (UC), 27 indeterminate colitis (IC) and 201 randomly selected controls, from Canterbury, New Zealand were screened for 3 common polymorphisms in the TNF-α receptor: -238 G→A, -308 G→A and -857C→T, using a TaqmanR assay. A meta-analysis was performed on the data obtained on these polymorphisms combined with that from other published studies. RESULTS: Individuals carrying the -308 G/A allele had a significantly (OR = 1.91, χ2 = 17.36, P < 0.0001) increased risk of pancolitis, and a 1.57-fold increased risk (OR = 1.57, χ2 = 4.34, P = 0.037) of requiring a bowel resection in UC. Carrying the -857 C/T variant decreased the risk of ileocolonic CD (OR = 0.56, χ2 =4.32, P = 0.037), and the need for a bowel resection (OR = 0.59, χ2 = 4.85, P = 0.028). The risk of UC was reduced in individuals who were smokers at diagnosis, (OR = 0.48, χ2 = 4.86, P = 0.028). CONCLUSION: TNF-α is a key cytokine known to play a role in inflammatory response, and the locus for the gene is found in the IBD3 region on chromosome 6p21, known to be associated with an increased risk for IBD. The -308 G/A SNP in the TNF-α promoter is functional, and may account in part for the increased UC risk associated with the IBD3 genomic region. The -857 C/T SNP may decrease IBD risk in certain groups. Pharmaco- or nutrigenomic approaches may be desir- able for individuals with such affected genotypes. | Lynnette R Ferguson Claudia Huebner Ivonne Petermann Richard B Gearry Murray L Barclay Pieter Demmers Alan McCulloch Dug Yeo Han | 2008 | World Journal of Gastroenterology2008，14，29： | 7 |
| 5 | Micro RNA biomarkers predicting risk,initiation and progression of colorectal cancer显示文摘Colorectal cancer is a major global cause of morbidity and mortality. Current strategies employed to increase detection of early,curable stages of this disease are contributing to a reduction of the negative health impact from it. While there is a genetic component to the risk of disease,diet and environment are known to have major effects on the risk of an individual for developing the disease. However,there is the potential to reduce the impact of this disease further b y preventing disease develop ment. Biomarkers which can either predict the risk for or early stages of colorectal cancer could allow intervention at a time when prospects could be modified by environmental factors,including lifestyle and diet choices. Thus,such biomarkers could be used to identify high risk individuals who would benefit from lifestyle and dietary interventions to prevent this disease. This review will give an overview on one type of biomarker in the form of micro RNAs,which have the potential to predict an individual's risk for colorectal cancer,as well as providing a highly sensitive and non-invasive warning of disease presence and/or progression. Micro RNA biomarkers which have been studied and whose levels look promising for this purpose include Mi R-18 a,Mi R-21,Mi R-92 a,Mi R-135 b,Mi R-760,Mi R-601. Not only have several individual micro RNAs appeared promising as biomarkers,but panels of these may be even more useful. Furthermore,understanding dietary sources and ways of dietary modulation of these micro RNAs might be fruitful in reducing the incidence and slowing the progression of colorectal cancer. | Kyungjin Lee Lynnette R Ferguson | 2016 | World Journal of Gastroenterology2016，22，33： | 3 |
| 6 | Role of β-microseminoprotein from prostate cancer initiationto recurrence: A mini-review显示文摘Medline/Pubmed articles relevant to this topic were considered using the search terms ?-microseminoprotein, MSMB, prostate secretory protein of 94 amino acids and PSP94. Full articles were retrieved when the abstract was considered relevant. In addition, other data related to this topic including our own are discussed. Summary of fi ndings-?-microseminoprotein(MSMB) is increasingly being considered as a marker for prostatecancer, as reduced levels have been associated with the disease. Here we review various aspects of this protein including its biological and physiological variants, binding proteins and immune modulation; its importance as a marker for biochemical recurrence of prostate cancer; prostate cancer related splice variants and its therapeutic utility. Two of the most important properties of MSMB are related to anticancer functions and immune modulation. Predominant expression of two(short and full-length) splice variants of MSMB has been observed from normal prostate and several other tissues. In benign prostate hyperplasia the short isoform is dominant, constituting 98% of this isoform, whereas in prostate cancer 96% constitute the fulllength isoform. The MSMB promoter single nucleotide polymorphism rs10993994 with the C allele functions as an activated cyclic adenosine monophosphate response element binding protein binding site. This C variant of rs10993994 could be responsible for the production of splice variants under variable conditions. MSMB has binding motifs to a few known proteins including immunoglobulin G and several Cysteine-rich secretory proteins family proteins. MSMB bound to these proteins is considered as immune modulating. Use of MSMB as a urinary marker for detecting aggressive prostate cancers that could resist radiation and surgical treatments, seems possible, but needs further investigation. The ratio of MSMB splice variants could also be a possible approach in understanding prostate cancers, with higher ratios indicating severe disease. | Nishi Karunasinghe Karen Bishop Pamela Murray Yuanye Xu Megan Goudie Lance Ng Shuotun Zhu Dug Yeo Han Lynnette R Ferguson Jonathan Masters Benji Benjamin Michael Holmes | 2014 | World Journal of Clinical Urology2014，3，1： | 2 |
| 7 | Role of plant polyphenols in genomic stability显示文摘 | Lynnette R. Ferguson | 2001 | Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis2001，，1： | 2 |
| 8 | Fish oils in parenteral nutrition: Why could these be important for gastrointestinal oncology?显示文摘By the time a gastroenterology patient is moved to parenteral nutrition, he or she is usually in poor health. All parenteral nutrition formulae contain essen-tial nutrients, avoiding components that could cause an adverse reaction. The lipid component is often provided by a soy extract, containing all the fatty acids considered to be essential in the diet. Several trials have considered parenteral nutrition formulas with added fish oils, high in the long chain omega-3 polyunsaturated fatty acids, eicosapentaenoic acid(EPA) and docosahexaenoic acid(DHA). Given the range of biological functions associated with such compounds, especially in reducing inflammatory symptoms, this move would appear rational. However, while data from such trials are often positive, there has been variability among results. Some of this variability could be caused by environmental contaminants in the fish, and/or oxidation of the lipids because of poor storage. The situation is complicated by a recent report that fish oils may counter the effects of platinum chemotherapy. However, this effect associated with a minor component, hexadeca-4,7,10,13-tetraenoic acid. It is suggested that pure DHA and EPA would be beneficial additions to parenteral nutrition, reducing the probability of carcinogenesis and enhancing rational disease management. However, the jury is still out on fish oils more generally. | Lynnette R Ferguson | 2015 | World Journal of Gastrointestinal Oncology2015，7，9： | 2 |
| 9 | Bacterial antimutagenesis by hydroxycinnamic acids from plant cell walls显示文摘 | Lynnette R. Ferguson Isabel Fong Lim Amira E. Pearson John Ralph Philip J. Harris | 2003 | MutRes-Genetic Toxicology and Environmental Mutagenesis2003，，1： | 1 |
| 10 | Gahctomannan, soluble sugar and starch mobilization following germination of Trugonella foenum-graecum seeds 显示文摘 | LYNNETTE M A ALEXANDER R DICK V | 1999 | Plant Physiological Biochemist1999，37，1： | 1 |
| 11 | Candidate gene association studies of the α4 ( CHRNA4 ) and b2 ( CHRNB2 ) neuronal nicotinic acetylcholine receptor subunit genes in Alzheimer's disease 显示文摘 | Lynnette J Luk W Alison E | 2004 | Neurosci Lett2004，358，： | 1 |
| 12 | Recovery of organic products from ionic liquids using supercritical carbon dioxide显示文摘 | Lynnette A Blanchard Joan F Brennecke | 2001 | Ind Eng Chem Res2001，30，： | 1 |
| 13 | The Hypothalamic-pituitary-adrenal axis in pregnancy: challenges in disease detection and treatment显示文摘 | John R Lindsay J Lynnette KN | 2005 | Endonr Rev2005，26，6： | 1 |
| 14 | The diagnosis of Cushing's syndrome:an endoscrine society clinical practice guideline 显示文摘 | Lynnette K Nieman M Beverly M | 2008 | J olin Endocrim Metab2008，1210，： | 1 |
| 15 | Magnetic resonance imaging and transvaginal ultrasound for determining fibroid burden: implications for research and clinical care显示文摘 | Eric D. Levens Robert Wesley Ahalya Premkumar Wendy Blocker Lynnette K. Nieman | 2009 | American Journal of Obstetrics and Gynecology2009，，5： | 1 |
| 16 | Prospects for cancer prevention显示文摘 | Lynnette R Ferguson | 1999 | Mutation Research1999，428，1999： | 1 |
| 17 | Comfort: exploration of the concept in nursing 显示文摘 | Ferrel M Lynnette LS | 2002 | Joumal of Advanced Nursing2002，39，6： | 1 |
| 18 | Selenium supplementation and human health显示文摘 | Lynnette R Ferguson P D | 2003 | Journal of Korean Association of Cancer Prevention2003，8，1： | 1 |
| 19 | Anthocyanidin-containing compounds occur in the periderm cell walls of the storage roots of sweet potato ( Ipomoea batatas )显示文摘 | Martin Philpott Lynnette R. Ferguson Kevin S. Gould Philip J. Harris | 2009 | Journal of Plant Physiology2009，，10： | 1 |
| 20 | Meat and cancer显示文摘 | LYNNETTE R F | 2010 | Meat Science2010，84，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员